Offer - Urjas Oil for just ₹ 1
Megavog MF 0.2/500 Tablet SR is a prescription drug, available for use as Tablet. Other than this, Megavog MF 0.2/500 Tablet SR has some other therapeutic uses, which have been discussed ahead.
The right dosage of Megavog MF 0.2/500 Tablet SR depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
The side effects typically associated with Megavog MF 0.2/500 Tablet SR include Weakness, Headache, Nausea or vomiting. Some other side effects of Megavog MF 0.2/500 Tablet SR have been listed ahead. Such side effects of Megavog MF 0.2/500 Tablet SR normally do not last long and go away once the treatment is completed. If, however, they worsen or do not go away, please speak with your physician.
In addition, Megavog MF 0.2/500 Tablet SR's effect is Severe during pregnancy and Severe for lactating mothers. Further, the section on Megavog MF 0.2/500 Tablet SR related warnings talks about Megavog MF 0.2/500 Tablet SR's effects on the liver, heart and kidney.
Megavog MF 0.2/500 Tablet SR can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Megavog MF 0.2/500 Tablet SR in conditions like Diabetic Ketoacidosis.
Besides this, Megavog MF 0.2/500 Tablet SR may also have severe interaction with some medicines. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Megavog MF 0.2/500 Tablet SR is considered not safe while driving, and is not addictive.
Megavog MF 0.2/500 Tablet SR is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| 13 - 18 years (Adolescent) |
|
| Adult |
|
| Geriatric |
|
Is the use of Megavog MF 0.2/500 Tablet SR safe for pregnant women?
Megavog MF can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Megavog MF 0.2/500 Tablet SR safe during breastfeeding?
Women who are breastfeeding may experience severe harmful effects after taking Megavog MF. It should only be taken after medical advice.
What is the effect of Megavog MF 0.2/500 Tablet SR on the Kidneys?
Megavog MF may cause harmful effects on kidney. if you feel its having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Megavog MF 0.2/500 Tablet SR on the Liver?
There may be an adverse effect on the liver after taking Megavog MF. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Megavog MF 0.2/500 Tablet SR on the Heart?
Very few cases of side effects of Megavog MF on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Megavog MF 0.2/500 Tablet SR unless your doctor advises you to do so -
Is this Megavog MF 0.2/500 Tablet SR habit forming or addictive?
No, there is no any evidence that Megavog MF 0.2/500 Tablet SR is addictive.
Is it safe to drive or operate heavy machinery when consuming?
After taking Megavog MF 0.2/500 Tablet SR, you should not drive or work on any heavy machine, as Megavog MF 0.2/500 Tablet SR can make you drowsy.
Is it safe?
Yes, but consume Megavog MF 0.2/500 Tablet SR only on doctor's advice.
Is it able to treat mental disorders?
No, the use of Megavog MF 0.2/500 Tablet SR in mental disorders is not effective.
Interaction between Food and Megavog MF 0.2/500 Tablet SR
Due to the absence of research, it is difficult to say how Megavog MF 0.2/500 Tablet SR and food will interact.
Interaction between Alcohol and Megavog MF 0.2/500 Tablet SR
It is difficult to say anything about the effect of Megavog MF 0.2/500 Tablet SR and alcohol. No research has been done on this yet.
Yes, Megavog MF can cause low blood sugar (hypoglycemia). However, this can also occur if you delay or miss a meal, drink alcohol, exercise more than usual, can't eat due to stomach upset, and taking other antidiabetic medicine with voglibose. So, regular monitoring of blood glucose level is needed and be cautious of symptoms of hypoglycemia. It is best to consult your doctor if you feel any unwanted effects.
Yes, Megavog MF is safe to use, if taken in prescribed amount and duration as advised by the doctor. However, certain side effects have been associated with this drug such as dizziness, nausea, and vomiting. If you experience any discomfort after taking this medicine then inform your doctor immediately and follow his/her instructions.
Megavog MF contain voglibose. It works by inhibiting the enzyme (alpha-glucosidase) that reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. Hence in this way, Megavog MF reduces blood sugar levels.
Yes, Megavog MF can cause night sweat, the exact mechanism of sweating is not known. But some research suggests that it causes hypoglycemia (low blood sugar) especially at night which leads to night sweats. You need to monitor your blood glucose level regularly and talk to your doctor as your dose may need to be adjusted.
Megavog MF should be taken as long as needed or take it as directed by doctor. Do not discontinue the drug suddenly or take it longer than prescribed by your doctor.
This medicine data has been created by -
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826